Program

11:50 – 12.00    Marko Jakopović: Introduction

Diagnostics and staging

Moderator: Bojan Zarić

12:00 – 12:20   Fran Seiwerth: Appropriate options for lung cancer diagnosis

12:20 – 12:35    Kristina Krpina: Initial results of National lung cancer screening program

12:35 – 12:50    Miroslav Samaržija: Predictive models in lung cancer screening

12:50 – 13:10    Maja Hrabak Paar: New TNM 9th edition staging proposal

13:10 – 13:30    Fran Borovečki: Comprehensive genomic profiling in thoracic oncology in Croatia

13:30 – 13:50   Bojan Zarić: The role of ctDNA in non-small cell lung cancer

14:20 – 14:40    Coffee break

Early stage lung cancer

Moderator: Davorin Radosavljević

14:40 – 15:00    Lovorka Batelja -Vuletić: Importance of MPR and pCR in the era of neodjuvant immunotherapy

15:00 – 15:20    Maximillian Hochmair: Peri-operative treatment of lung cancer

Radiotherapy

Moderator: Tihana Boraska Jelavić

15:20 – 15:40    Tihana Pavić: Modern radiotherapy in thoracic oncology

15:40 – 16:00    Marko Jakopović: Stage III lung cancer – concomitant or sequential CRT in the era of immunotherapy                                       

16:30 – 16:50    Coffee break

Special considerations

Moderator: Davorin Radosavljević

16:50 – 17:10    Sonja Badovinac: Endobronchial interventions in lung cancers – indications and outcomes

17:10 – 17: 30   Luka Simetić: Thoracic sarcomas

17:30 – 17: 50   Tomi Kovačević: The role of cannabinoids in palliative care of lung cancer patients

17:50 – 18:10    Sandra Karabatić: What is the role of lung cancer nurse in lung cancer pathway through the disease?                                        

20:00 Get together

Small-cell lung cancer

Moderator: Urška Janžić

09:00 – 09:20    Dražena Srdić: Systemic treatment of SCLC – current standards and future options

09:20 – 09:40    Tihana Boraska Jelavić: Radiation therapy in extensive stage SCLC – thoracic and brain                                   radiotherapy in the era of immunotherapy

09:40 – 10:00    Dorian Hiršl: The role of surgery in small – cell lung cancer

Targeted treatments

Moderator: Katja Mohorčić

09:00 – 09:20    Lela Bitar: Treatment of EGFR positive lung cancer patients

09:20 – 09:40    Sanja Pleština: How to choose upfront ALK inhibitor?

09:40 – 10:00    Urška Janžić: New targets in NSCLC – treatment options

10:00 – 10:20    Jasna Radić: Antibody – drug conjugates in lung cancer – therapeutic implications

10:50-11:10        Coffee break

Immunotherapy

Moderator: Davorin Radosavljević

11:10 – 11:20     Marko Jakopović: Is immunotherapy a game changer? Introduction to the session

11:20 – 11:40    Katja Mohorčić: Mono vs combo immunotherapy in patients with expression of PD-L1 ≥ 50% 

11:40 – 12:00    Suzana Mladinov: Optimal duration of immunotherapy in NSCLC

12:00 – 12:20     Marijo Boban: Re-challenge of immunotherapy – when and why?

12:20 – 12:40    Ivana Canjko: Side – effects of immunotherapy – special considerations in the era of combination                                 therapies

Special considerations

Moderator: Tihana Boraska Jelavić

12:40 – 13:00    Feđa Džubur: Indications for ICU admission in lung cancer patients or when not to turn down                                 admission of lung cancer patient in ICU?

13:00 – 13:20    Vide Popović: Pleural mesothelioma

13:20 – 13:40    Marko Jakopović: Is chemotherapy dead?

13:40 – 14:00    Latinka Basara: Approach to lung cancer patient – psychologist point of view

14:00 – 14:20 Davorin Radosavljević: What will future of treatment of lung cancer look like?

14:20 Closing remarks